Important role of 3-methoxytyramine in the inhibition of cocaine sensitization by 1-methyl-1,2,3,4-tetrahydroisoquinoline: An in vivo microdialysis study

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 983-997

  Wa̧sik, Agnieszka ^a   Romańska, Irena ^a   Antkiewicz Michaluk, Lucyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1 methyl 1,2,3,4 tetrahydroisoquinoline; 3 methoxytyramine; Cocaine sensitization; Dopamine release; Microdialysis study; Wistar rats

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; COCAINE; DOPAMINE; DRUGS USED IN THE TREATMENT OF ADDICTION; HOMOVANILLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG MECHANISM; HISTOPATHOLOGY; HYPERACTIVITY; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; RAT; WISTAR RAT;

EID: 79551501377     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70360-1     Document Type: Article

References (86)

1. Akimoto K, Hamamura T, Otsuki S: Subchronic cocaine treatment enhances cocaine-induced dopamine efflux, studies by in vivo intracerebral dialysis. Brain Res, 1989, 490, 339-344. (Pubitemid 19158566)
2. Antkiewicz-Michaluk L, Filip M, Kostowski W, Patsenka A, Popik P, Przegaliński E, Wróbel M: 1-Methyl- 1,2,3,4-tetrahydroisoquinoline attenuates ethanol, cocaine and morphine addiction in behavioral models: neurochemical correlates. Acta Neurobiol Exp, 2005, 65, P3.01 p. 321.
3. Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegaliński E, Vetulani J: An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm, 2007, 114, 307-317.
4. Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski A, Vetulani J: 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol, 2003, 466, 263-269.
5. Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, Kajta M, Ziemińska E, Salińska E, Wa̧sik A et al.: The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem, 2006, 97, 846-856.
6. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Otha S, Vetulani J: Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem, 2001, 78, 100-108.
7. Antkiewicz-Michaluk L, Michaluk J, Romańska I, Papla I, Vetulani J: Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm, 2000, 107, 1009-1019.
8. Antkiewicz-Michaluk L, Ossowska K, Romańska I, Michaluk J, Vetulani J: 3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity. Eur J Pharmacol, 2008, 599, 32-35.
9. Antkiewicz-Michaluk L, Romańska I, Papla I, Michaluk J, Bakalarz M, Vetulani J, Krygowska-Wajs A, Szczudlik A: Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain. Neuroscience, 2000, 96, 59-64.
10. Antkiewicz-Michaluk L,Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol, 2004, 7, 155-163.
11. Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, Carr K, Hall S: Haloperidol antagonism of cue-elicited cocaine craving. Lancet, 1996, 347, 504-508.
12. Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S et al.: Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem, 2003, 46, 3822-3839.
13. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F: One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry, 1994, 51, 989-997.
14. Cornish JL, Duffy P, Kalivas PW: A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience, 1999, 93, 1359-1367.
15. De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A: Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol, 1995, 6, 562-567.
16. De Wit H, Wise RA: Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol, 1977, 31, 195-203.
17. Di Chiara G: The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend, 1995, 38, 95-137.
18. 1b-Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci, 2002, 22, 2873-2884.
19. Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F et al.: Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend, 2006, 85, 191-197.
20. Filip M, Antkiewicz-Michaluk L, Zaniewska M, Frankowska M, Gołda A, Vetulani J, Przegaliński E: Effects of 1-methyl-1,2,3,4- tetrahydroisoquinoline on the behavioral effects of cocaine in rats. J Physiol Pharmacol, 2007, 58, 625-639.
21. 3 receptor ligand with therapeutic potential for treatment of cocaine-addiction. CNS Drug Rev, 2003, 9, 141-158.
22. Garzon J, Fuentes J, Del Rio J: Effect of selective monoamine oxidase inhibitor drugs on morphine tolerance and physical dependence in mice. Neuropharmacology, 1979, 18, 531-536.
23. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol, 2006, 17, 151-159. (Pubitemid 43312590)
24. Gawin FH: Cocaine addiction: psychology and neurophysiology. Science, 1991, 251, 1580-1586.
25. Gifford AN, Johnson KM: Effect of chronic cocaine treatment on D2 receptors regulating the release of dopamine and acetylcholine in the nucleus accumbens and striatum. Pharmacol Biochem Behav, 1992, 41, 841-846.
26. Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry, 2002, 159, 1642-1652.
27. Grasing K, He S: Effects of high-dose of selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav Pharmacol, 2005, 16, 1-13. (Pubitemid 40354361)
28. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y: Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci, 2003, 23, 742-747. (Pubitemid 36206164)
29. Guan LC, Robinson TE, Becker JB: Sensitization of rotational behavior produced by a single exposure to cocaine. Pharmacol Biochem Behav, 1985, 22, 901-903.
30. Heidbreder CA, Hagan JJ: Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Curr Opin Pharmacol, 2005, 5, 107-118. (Pubitemid 40124543)
31. Heikkila RE, Manzino L: Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol, 1984, 103, 241-248.
32. Hemby SE, Smith JE, Dworkin SI: The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats. J Pharmacol Exp Ther, 1996, 277, 1247-1258.
33. Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE: Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology, 2004, 172, 31-40. (Pubitemid 38299748)
34. Howell LL, Wilcox KM: The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther, 2001, 298, 1-6.
35. Howell LL, Wilcox KM, Lindsey KP, Kimmel HL: Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys. Neuropsychopharmacology, 2006, 31, 585-593.
36. Hurd YL, Weiss F, Koob GF, Ungerstedt N-EU: Cocaine reinforcement and extracellular dopamine overflow in rat nucleus accumbens: an in vivo microdialysis study. Brain Res, 1989, 498, 199-203.
37. 2 receptors in the mouse striatum. J Neurochem, 2001, 79, 868-876.
38. Jiménez-Rivera CA, Felieu-Mojer M, Vazquez-Torres R: Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann NY Acad Sci, 2006, 1074, 390-402.
39. 2A-Adrenoceptors regulate D-amphetamine-induced hyperactivity and behavioural sensitization in mice. Eur J Pharmacol, 2005, 517, 74-83.
40. Kalivas PW: Glutamate systems in cocaine addiction. Curr Opin Pharmacol, 2004, 4, 23-29.
41. Kalivas PW, Duffy P: The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse, 1990, 5, 48-58.
42. Kalivas PW, Duffy P: Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci, 1993, 13, 266-275.
43. Kalivas PW, Duffy P, Du Mars LA, Skinner C: Behavioral and neurochemical effects of acute and daily cocaine administration in rats. J Pharmacol Exp Ther, 1988, 245, 485-492.
44. Karoum F, Chrapusta SJ, Brinjak R, Hitri A, Watt RJ: Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br J Pharmacol, 1994, 113, 1391-1399.
45. Karoum F, Chrapusta SJ, Egan MF: 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem, 1994, 63, 972-979.
46. Kleven MS, Woolverton WL: Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend, 1993, 31, 149-58.
47. Kohno M, Otha S, Hirobe M: Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Commun, 1986, 140, 448-454. (Pubitemid 17190044)
48. Koob GF, Nestler EJ: The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci, 1997, 9, 482-497.
49. Kotake Y, Taguchi R, Okuda K, Sekiya Y, Tasaki Y, Hirobe M, Ohta S: Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res, 2005, 1033, 143-50.
50. Kuhar MJ, Ritz MC, Boja JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci, 1991, 14, 299-302.
51. Le Foll B, Goldberg SR, Sokoloff P: The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology, 2005, 49, 525-541.
52. 3 receptor agents as potential new medications for drug addictions. Eur Psychiatry, 2000, 15, 140-146.
53. Lienau AK, Kuschinsky K: Sensitization phenomena after repeated administration of cocaine or D-amphetamine in rats: associative and non-associative mechanisms and the role of dopamine in the striatum. Naunyn Schmiedeberg's Arch Pharmacol, 1997, 355, 531-537.
54. 3 receptor ligands. Chembiochem, 2004, 5, 508-518.
55. Mc Naught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiat, 1994, 55, 47-52.
56. Meil WM, Schechte MD: Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol, 1997, 340, 17-26.
57. 1 receptors in rhesus monkeys. Synapse, 1998, 28, 1-9.
58. 2 receptors in rhesus monkeys. Synapse, 1998, 30, 88-96.
59. Narayanan S, Willins D, Dalia A, Wallace L, Uretsky N: Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav, 1996, 54, 565-573. (Pubitemid 26180197)
60. Ossowska K, Wardas J, Kuter K, Nowak P, Da̧browska J, Bortel A, Labus Ł et al.: Influence of paraquat on dopaminergic transporter in the rat brain. Pharmacol Rep, 2005, 57, 330-335.
61. Patsenka A, Antkiewicz-Michaluk L: Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds -1,2,3,4- tetrahydroisoquinoline alkaloids. Pol J Pharmacol, 2004, 56, 727-734.
62. 3H]-dopamine release. Pharmacol Biochem Behav, 1987, 27, 533-535.
63. Pettit HO, Pan H-T, Parsons LH, Justice JB Jr: Extracellular concentration of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem, 1990, 55, 798-804.
64. Pierce RC, Kalivas PW: A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev, 1997, 25, 192-216.
65. Pietraszek M, Michaluk J, Romańska I, Wa̧sik A, Gołembiowska K, Antkiewicz-Michaluk L: 1-Methyl-1,2,3,4- tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res, 2009, 16, 390-407.
66. 3 receptor agonist. Nature, 1999, 400, 371-375.
67. Preti A: BP-897 Bioprojet. Curr Opin Investig Drugs, 2000, 1, 110-115.
68. Pulvirenti L, Maldonado-Lopez R, Koob GF: NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res, 1992, 594, 327-330.
69. Reith ME, Meisler BE, Sershen H, Lajtha A: Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol, 1986, 35, 1123-1129. (Pubitemid 16075529)
70. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ: Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 1987, 237, 1219-1223.
71. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev, 1993, 18, 247-291.
72. Schiffer WK, Azmoodeh M, Gerasimov M, Volkow ND, Fowler JS, Dewey SL: Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse, 2003, 48, 35-38. (Pubitemid 36249889)
73. Segal DS, Geyer MA, Schuckit MA: Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol, 1981, 5, 95-129.
74. Segal DS, Kuczenski R: Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res, 1992, 577, 351-355.
75. Smelson DA, Williams J, Ziedonis D, Sussner BD, Losonczy MF, Engelhart C, Kaune M: A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat, 2004, 27, 45-49. (Pubitemid 38829778)
76. Tzschentke TM, Schmidt WJ: Glutamatergic mechanisms in addiction. Mol Psychiatry, 2003, 8, 373-382.
77. Vetulani J: Drug addiction. Part II. Neurobiology of addiction. Pol J Pharmacol, 2001, 53, 303-317.
78. Vetulani J, Antkiewicz-Michaluk L, Nalepa I, Sansone M: A possible physiological role for cerebral tetrahydroisoquinolines. Neurotox Res, 2003, 5, 147-156
79. Villegier AS, Drouin C, Bizot JC, Marien M, Glowinski J, Colpaert F, Tassin JP: Stimulation of postsynaptic α1b- and α2-adrenergic receptors ampliflies dopamine-mediated locomotor activity in both rats and mice. Synapse, 2003, 50, 277-284.
80. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S et al.: Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature, 1997, 386, 827-830.
81. Wa̧sik A, Patsenka A, Antkiewicz-Michaluk L: An endogenous compound 1-methyl-1,2,3,4-tetrahydroisoquinoline prevents the morphine addiction in rat: the view on neurochemical mechanism of action. Eur Neuropsychopharmacol, 2005, 15, Suppl, 22-23.
82. Wa̧sik A, Romańska I, Antkiewicz-Michaluk L: The effect of an endogenous compoud 1-methyl-1,2,3,4-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol, 2007, 58, 235-252.
83. Wise RA: Neural mechanisms of the reinforcing action of cocaine. NIDA Res Monogr, 1984, 50, 15-33.
84. 2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav, 1986, 24, 531-535.
85. Woolverton WL, Johnson KM: Neurobiology of cocaine abuse. Trends Pharmacol Sci, 1992, 13, 193-200.
86. Zhang Y, Loonam TM, Noailles PA, Angulo JA: Comparison of cocaine- and amphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann NY Acad Sci, 2001, 937, 93-120.